Endometrial cancer affects more than 45,000 women a year in the U.S., usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known preventive medication for women at high risk of developing it.
"The results of the study suggest that use of low bone density medications may have a protective effect on endometrial cancer, or that women who take them get a less-aggressive cancer," says Sharon Hensley Alford, Ph.D, lead author of the study, and a researcher in Public Health Services at Henry Ford Hospital.
The classification for these medications is bisphosphonates.
In the fifth year of the ongoing trial, all participants were asked to complete a supplemental questionnaire, which included questions about their use of medications that treat thinning bones.
A total of 29,254 women were included in the analysis, for which 115 endometrial cancers have been diagnosed since the completion of the questionnaires.
The rate of endometrial cancer among women who had taken bisphosphonates was approximately half that of women who had never taken the medication (9.6 vs. 18.7 per 10,000 person years). The effect was more significant with less-aggressive cancers.
Dr. Alford is presenting the study March 24 at the Society of Gynecologic Oncology's 2012 Annual Meeting on Women's Cancer in Austin, Texas.
Henry Ford researchers used data from the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian Screening Trial, which collected data on all cancer outcomes for trial participants.
At the time the women were recruited for the trial, they ranged from 55 to 70 years old.
Women with missing information on bone medication use were excluded. Only women who had not had a hysterectomy were included in the analysis.
Women without a cancer diagnosis at the time of the questionnaire were separated into groups: those who reported current or past use of a bisphosphonate, defined as "ever used", and women who had never used such medications.
This study alone would not change clinical practice, and more study is necessary, according to Dr. Alford.
"This was a retrospective study, with self-reported data," says Dr. Alford. "A clinical trial, with closely monitored data, needs to be done for definitive results."
The study was funded by the National Cancer Institute and Henry Ford Health System.
Sally Ann Brown | EurekAlert!
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Disarray in the brain
18.12.2017 | Universität zu Lübeck
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
19.01.2018 | Materials Sciences
19.01.2018 | Health and Medicine
19.01.2018 | Physics and Astronomy